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ABSTRACT 45 
Background: The contribution of ectopic lymphoid tissues (eLTs) to local 46 
immunoglobulin (Ig) hyperproduction in chronic rhinosinusitis with nasal polyps 47 
(CRSwNP) is unclear.  48 
Objective: We sought to explore the cellular basis, formation mechanisms, and 49 
function of eLTs in CRSwNP.  50 
Methods: We graded lymphoid aggregations in sinonasal mucosa and histologically 51 
studied their structures. The expression of lymphorganogenic factors and molecules 52 
required for Ig production was measured using real-time PCR and their localization 53 
was analyzed by immunohistochemistry and immunofluorescence. The phenotype of 54 
T follicular helper (TFH) cells was analyzed by performing flow cytometry. Ig levels 55 
were quantified by using Bio-Plex assay or ImmunoCAP system. Nasal tissue 56 
explants were challenged ex vivo with Dermatophagoides pteronyssinus group 1 (Der 57 
p1), and the expression of Iε-Cµ and Iε-Cγ circle transcripts was detected using 58 
semi-nested PCR. 59 
Results: Increased formation of eLTs with germinal center-like structures was 60 
discovered in eosinophilic (20.69%) and non-eosinophilic CRSwNP (17.31%) 61 
compared to chronic rhinosinusitis without nasal polyps (5.66%) and controls (3.70%). 62 
The presence of eLTs was associated with increased expression of lymphorganogenic 63 
and inflammatory chemokines and cytokines, as well as their receptors. The 64 
expression of molecules required for Ig production, the generation of TFH cells, and 65 
the production of IgE in eosinophilic polyps and IgG and IgA in both eosinophilic and 66 
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non-eosinophilic polyps were predominantly up-regulated in cases with eLTs. After 67 
the challenge of Der p1 ex vivo, Iε-Cµ transcript was only detected in eosinophilic 68 
polyps with eLTs but not in those without eLTs and non-eosinophilic polyps.  69 
Conclusion: eLTs may support local Ig production and therefore significantly 70 
contribute to the development of CRSwNP. 71 
 72 
Key words: Ectopic lymphoid tissue, immunoglobulin, lymphoid aggregate, 73 
lymphorganogenesis.  74 
 75 
Clinical implication: Therapeutic strategies that target ectopic lymphoid tissues in 76 
nasal polyps may inhibit local immunoglobulin production and disease progression. 77 
 78 
Capsule summary: Lymphorganogenic chemokines, survival factors, and 79 
lymphotoxin orchestrate the cellular organization of eLTs in nasal polyps, which 80 
likely support local Ig production and exacerbate CRSwNP. 81 
 82 
 83 
 84 
 85 
 86 
 87 
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AID: activation-induced cytidine deaminase 89 
BAFF: B cell-activating factor of the tumor necrosis factor family 90 
Bcl-2: B cell lymphoma 2  91 
CCL19: chemokine (C-C motif) ligand 19 92 
CCL20: chemokine (C-C motif) ligand 20 93 
CCL21: chemokine (C-C motif) ligand 21 94 
CCR6: C-C chemokine receptor 6 95 
CCR7: C-C chemokine receptor 7  96 
CRSwNP: chronic rhinosinusitis with nasal polyps 97 
CRSsNP: chronic rhinosinusitis without nasal polyps 98 
CXCL12: chemokine (C-X-C motif) ligand 12 99 
CXCL13: chemokine (C-X-C motif) ligand 13 100 
CXCR4: C-X-C chemokine receptor 4 101 
CXCR5: C-X-C chemokine receptor 5  102 
DC: dendritic cell  103 
Der p1: Dermatophagoides pteronyssinus group 1 104 
ENP: eosinophilic nasal polyp 105 
eLTs: ectopic lymphoid tissues  106 
FDC: follicular dendritic cell 107 
GC: germinal center 108 
HEV: high endothelial venule 109 
Ig: immunoglobulin 110 
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ICAM1: intercellular adhesion molecule 1 111 
ICOS: inducible costimulator 112 
LIGHT: tumor necrosis factor superfamily member 14 113 
LTα: lymphotoxin alpha 114 
LTβ: lymphotoxin beta 115 
LTβR: lymphotoxin beta receptor 116 
NENP: non-eosinophilic nasal polyp 117 
NP: nasal polyp 118 
PD1: programmed cell death protein 119 
PNAd: peripheral node addressin 120 
TFH: T follicular helper  121 
VCAM1: vascular cell adhesion molecule 1 122 
 123 
 124 
 125 
 126 
 127 
 128 
 129 
 130 
 131 
INTRODUCTION 132 
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Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by 133 
exaggerated inflammation in sinonasal mucosa and formation of polyps.1 Medical 134 
treatments usually involve nonspecific suppression of chronic inflammation and are 135 
ineffective in many patients, reflecting our limited understanding of the complicated 136 
cellular and molecular networks in CRSwNP.1 An array of evidence has implicated a 137 
critical role of local immunoglobulin (Ig) hyperproduction in the pathogenesis of 138 
CRSwNP.2, 3 IgE antibodies against aeroallergens and Staphylococcus aureus 139 
enterotoxins were identified in nasal polyps (NPs), which could activate mast cells 140 
upon allergen exposure and were correlated with local eosinophilia.4, 5 Additionally, 141 
autoreactive antibodies, such as anti-double stranded DNA IgG and anti-BP180 IgG, 142 
have recently been demonstrated in NPs and potentially linked with mucosal 143 
complement activation.6-8 Increased IgA levels have also been reported in NPs and 144 
may contribute to eosinophil activation.9 Importantly, higher local IgE and IgG levels 145 
were found to associate with poorly controlled disease in CRSwNP patients even after 146 
surgical intervention.4, 6 147 
Currently, the mechanisms underlying local Ig hyperproduction in CRSwNP are 148 
poorly understood. Antigen-driven antibody affinity maturation, isotype switch, and 149 
memory formation usually take place within germinal centers (GC) formed in 150 
secondary lymphoid organs such as spleens or lymph nodes. Nevertheless, increased 151 
accumulation and activation of B cells, driven by up-regulated expression of B-cell 152 
chemokines and activating factors, have been demonstrated in NPs.9, 10 Local IgE 153 
levels were up-regulated in patients with eosinophilic CRSwNP independent of 154 
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systemic atopy.4, 11 Moreover, receptor revision and class switching to IgE could occur 155 
in NPs, implicating a potential local antibody response and GC reaction in NPs.11, 12 156 
Indeed, ectopic lymphoid tissues (eLTs) have been found in NPs.13-16 However, the 157 
cellular basis, formation mechanisms, and function of polyp eLTs remain to be 158 
defined.  159 
The purpose of this study was to investigate (1) the size and structure of 160 
lymphoid aggregates in NPs and their frequency in patients, and the relationship 161 
between lymphoid aggregates and eLTs characterized by the presence of GC-like 162 
structures; (2) the potential mechanisms underlying the lymphoid neogenesis in NPs, 163 
and (3) the function of eLTs in local Ig production and its clinical relevance in 164 
CRSwNP. 165 
 166 
METHODS  167 
Subjects  168 
This study was approved by the Ethics Committee of Tongji Hospital and 169 
conducted with written informed consent from each patient. The diagnosis of 170 
CRSwNP and chronic rhinosinusitis without nasal polyps (CRSsNP) was made 171 
according to the current European Position Paper on Rhinosinusitis and Nasal Polyps 172 
(EPOS).1 CRSwNP was defined as eosinophilic when the percentage of tissue 173 
eosinophils exceeded 10% of total infiltrating cells, as reported by our previous 174 
study.17 This cut-off was calculated as twice the standard deviation of the mean of 175 
eosinophil percentages in controls.17 Subjects undergoing septoplasty because of 176 
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anatomic variation and without other sinonasal diseases were enrolled as controls.11, 17 177 
Polyp tissues from CRSwNP patients, diseased sinus mucosa from CRSsNP patients, 178 
and inferior turbinate mucosal tissues from control subjects were obtained during 179 
surgery. Demographic characteristics of enrolled subjects are listed in Table E1, and 180 
additional information is provided in this article’s Online Repository.  181 
 182 
Histology study 183 
Tissue sections were stained with hematoxylin-eosin, and lymphocyte 184 
aggregation was graded according to a previously described method.18, 19 Each sample 185 
was graded according to the highest level of lymphoid aggregation present.18 Cell 186 
aggregates with a radial cell count between 2 and 5 cells were classified as Grade 1, 187 
those with 6 to 10 cells were classified as Grade 2, while those with more than 10 188 
radial cells were classified as Grade 3.18, 19 The number of lymphoid aggregates was 189 
counted at a low power magnification (× 100). More information is provided in this 190 
article’s Online Repository. 191 
 192 
Immunohistochemistry and immunofluorescence 193 
Structures of lymphoid aggregates were evaluated by immunohistochemistry and 194 
immunofluorescence as previously described in prior researches.17, 20-22 Antibodies 195 
used are listed in Tables E2 and E3. More information is provided in this article’s 196 
Online Repository. 197 
 198 
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Measurement of Igs, chemokines and cytokines  199 
Ig and chemokine levels in tissues, and cytokine levels in culture supernatants 200 
were detected by using ImmunoCAP system, Bio-Plex assay, Q-Plex assay, or ELISA 201 
as previously reported.11, 15, 23, 24 More information is provided in this article’s Online 202 
Repository including Tables E4-E6.  203 
  204 
Reverse transcription polymerase chain reaction 205 
Quantitative RT-PCR was performed with specific primers (Table E7) as stated 206 
elsewhere.11, 17 The specific circle transcripts Iε-Cµ, Iε-Cγ, Iε-Cγ1, Iε-Cγ3, and Iε-Cγ4 207 
were investigated using a semi-nested PCR with appropriate primers (Table E8) as 208 
previously described.11, 25 More information is provided in this article’s Online 209 
Repository. 210 
 211 
Ex vivo allergen challenge 212 
Sinonasal mucosal tissues obtained from 5 controls without local specific IgE 213 
(sIgE) against Dermatophagoides pteronyssinus group 1 (Der p1) and not having eLTs, 214 
9 eosinophilic CRSwNP patients with local sIgE against Der p1 (5 of them having 215 
eLTs in NPs), and 8 non-eosinophilic CRSwNP patients without local sIgE against 216 
Der p1 (4 of them having eLTs in NPs) were subject to ex vivo air-liquid interface 217 
culture.25-27 Tissue explants were stimulated with recombinant Der p1 (20 µg/mL, 218 
endotoxin ≤ 0.03 EU/µg; Indoor Biotechnologies, Charlottesville, VA, USA) for 24 219 
hours as mentioned previously.25-27 After stimulation, tissue explants and culture 220 
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supernatants were harvested for further analysis. More information is provided in this 221 
article’s Online Repository. 222 
 223 
Flow cytometry 224 
The flow cytometric analysis of nasal mucosal mononuclear cells (NMCs) was 225 
performed as previously described.15, 20 More information is provided in this article’s 226 
Online Repository including Table E9. 227 
 228 
Statistics 229 
Statistical analysis was performed using the SPSS 18.0 software (SPSS Inc., 230 
Chicago, IL, USA). For continuous variables, results are presented in dot plots unless 231 
specifically stated. Symbols represent individual samples; horizontal bars represent 232 
medians, and error bars show interquartile ranges. When comparisons were made 233 
between groups, the Kruskal-Wallis H test was used to assess significant intergroup 234 
variability. The Mann-Whitney U 2-tailed test was used for between-group 235 
comparison. Chi-square test or Fisher’s exact test was applied to compare the 236 
differences in proportions between groups. Spearman rank test was used for 237 
correlations. Significance was accepted at P < 0.05.  238 
 239 
RESULTS 240 
Increased formation of lymphoid aggregates in NPs  241 
We analyzed a large cohort of surgical samples from patients with eosinophilic 242 
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and non-eosinophilic CRSwNP using hematoxylin-eosin staining and found that 243 
lymphoid aggregates were present in about half of the samples, in contrast to 19.26% 244 
of control samples (Fig E1, A-C). Lymphoid aggregates were graded on size. 245 
Lymphoid aggregates of each grade were found in higher frequency in eosinophilic 246 
and non-eosinophilic NPs as compared with controls (Fig E1, C and Table E10). 247 
Consistently, eosinophilic or non-eosinophilic NPs samples had higher numbers of 248 
lymphoid aggregates, as compared with controls, by total numbers or numbers of each 249 
grade (Fig E1, D). In some samples, aggregates in different grades could be 250 
discovered simultaneously (Fig E1, E).  251 
 252 
Diversified structures of lymphoid aggregates in NPs  253 
We investigated the structures of lymphoid aggregates in different grades by 254 
immunostaining samples from a subgroup of subjects, using tonsils as staining 255 
positive controls (Fig E2). We found that lymphoid aggregates in the same grade 256 
usually displayed a similar structure. There was no noticeable difference in the 257 
structures between lymphoid aggregates in eosinophilic and non-eosinophilic NPs 258 
(Table 1). Lymphoid aggregates with GC-like structures, characterized by the 259 
presence of Ki-67+ proliferating B cells, CD21+ follicular dendritic cell (FDC) 260 
networks, and peripheral node addressin (PNAd)+ high endothelial venules (HEVs), 261 
were defined as eLTs (Fig 1).19 We found that eLT development was associated with 262 
larger lymphoid aggregation, i.e. higher grade (Table 1). The eLTs were discovered in 263 
the majority of grade 2 (64.29%) and 3 (92.31%) lymphoid aggregates but absent in 264 
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grade 1 lymphoid aggregates (Table 1). The eLTs presented more frequently in 265 
eosinophilic (20.69%) and non-eosinophilic NPs (17.31%) compared with controls 266 
(3.70%) (Fig 2). No increase of eLT formation was found in diseased sinus mucosa 267 
from CRSsNP patients (5.66%) (Fig 2). In addition to HEVs, lymphatic vessels were 268 
also found in eLTs (Fig 1, B). HEVs were typically observed inside follicles, whereas 269 
lymphatic vessels were found mostly surrounding the follicles, in polyp eLTs (Fig 1, 270 
B). These specialized vascular and canalicular systems are essential for regulating 271 
leukocyte traffic and compartmentalization. In polyp eLTs, CD11c+ DCs infiltrated in 272 
follicles, and CD138+ plasma cells were found surrounding the follicles (Fig 1, B and 273 
D). In addition, innate immune cells including CD68+ macrophages and CD56+ 274 
natural killer cells were found inside or surrounding the follicles (Fig 1, B). Compared 275 
with follicles in tonsils, polyp eLTs did not have clear T-cell zone and polarized 276 
B-cell follicle (Fig 1 and Fig E2).  277 
 278 
Up-regulated expression of lymphorganogenic chemokines and cytokines in eLTs 279 
in NPs 280 
The formation of eLTs is initiated by the local recruitment and 281 
compartmentalization of T cells, B cells, and DCs under the coordination of 282 
homeostatic chemokines.28, 29 In order to investigate the potential mechanisms 283 
underlying the lymphoid neogenesis in NPs, we investigated the association between 284 
eLT formation and mRNA expression of chemokine (C-X-C motif) ligand 12 285 
(CXCL12)/C-X-C chemokine receptor 4 (CXCR4), CXCL13/CXCR5, chemokine 286 
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(C-C motif) ligand 20 (CCL20)/C-C chemokine receptor 6 (CCR6), and CCL19 and 287 
CCL21/CCR7 in NPs. Compared with those without eLTs or control samples, the 288 
mRNA expression levels of all tested chemokines and chemokine receptors were 289 
comparably elevated in eosinophilic and non-eosinophilic NPs with eLTs except for 290 
CXCL12 and CCL20 (Fig 3, A). We further measured the tissue protein levels of 291 
CXCL13 and CCL21, two critical chemokines for lymphoid organ formation, and 292 
confirmed their increased expression in NPs with eLTs (Fig E3). 293 
Immunohistochemistry and immunofluorescence demonstrated that CXCL13 was 294 
mainly expressed by FDCs and B cells inside follicles and CCL21 expression was 295 
mostly observed in endothelial cells surrounding the follicles in areas where HEVs 296 
and lymphatic vessels were observed in polyp eLTs (Fig 3, B and C). CXCR5+ B cells 297 
and CCR7+ T cells were enriched within polyp eLTs (Fig 3, D). In addition to eLTs, 298 
scattered CXCL13+ mononuclear cells, CCL21+ stromal cells, CXCR5+ cells, and 299 
CCR7+ cells were also discovered in other areas in polyps (Fig E4).  300 
The expression of lymphorganogenic chemokines is usually under the control of 301 
lymphotoxin (LT) β receptor (LTβR) signaling.28-30 LTβR signaling is also crucial for 302 
the expression of enzymes regulating PNAd expression.31 We found that eosinophilic 303 
and non-eosinophilic NPs with eLTs had comparably up-regulated mRNA expression 304 
of LTβR ligands including LTα, LTβ and tumor necrosis factor superfamily member 305 
14 (LIGHT) compared with NPs without eLTs and controls (Fig 4, A). Consistently, 306 
the protein levels of LTα were up-regulated in eosinophilic and non-eosinophilic NPs 307 
with eLTs (Fig E3). In addition, we discovered the presence of LTα, LTβ, and LTβR 308 
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expressing cells inside and surrounding the follicles in polyp eLTs (Fig 4, B). LTβR+ 309 
B cells were mainly detected in follicles and a few of them were also found in other 310 
areas besides eLTs in polyps (Fig 4, C and Fig E4). Recent studies suggest that IL-17 311 
may contribute to the development of eLTs in chronically inflamed tissues.32 Th17 312 
cells and IL-17 are able to trigger maturation of FDC network and upregulate the 313 
expression of CXCL13 and CCL19 independent of lymphotoxin.29, 33 Our previous 314 
studies reported the accumulation of Th17 cells in NPs.20, 34 In the present study, we 315 
further found that the mRNA expression of IL-17A, IL-17F and their receptor 316 
(IL-17RA) was mainly up-regulated in eosinophilic and non-eosinophilic NPs with 317 
eLTs, and no significant difference was found between two types of NPs (Fig 4, A). 318 
IL-17A+ cells were identified inside and surrounding the eLTs and in other areas in 319 
polyps (Fig 4, C and Fig E5). Compared with controls, the number of IL-17A+ cells 320 
was increased in both eosinophilic and non-eosinophilic polyps with a more 321 
prominent increase in those with eLTs (Fig E5). As another cytokine involved in the 322 
initiation and maintenance of eLTs within tissues,29 IL-7 is considered to promote 323 
lymphocyte survival by inducing the expression of anti-apoptotic factor B cell 324 
lymphoma 2 (Bcl-2) and to regulate early lymphatic vessel expansion.21 We found 325 
that both IL-7 and IL-7R mRNA levels were up-regulated similarly in eosinophilic 326 
and non-eosinophilic NPs with eLTs compared with controls and NPs without eLTs 327 
(Fig 4, A). Immunofluorescence demonstrated IL-7 expression in eLTs and scattered 328 
IL-7+ cells were also found in other locations other than eLTs (Fig 4, C and Fig E6). 329 
HEVs express adhesion molecules, such as intercellular adhesion molecule 1 (ICAM1) 330 
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and vascular cell adhesion molecule 1 (VCAM1), which promote the accumulation of 331 
naïve lymphocytes from the blood.28, 29 We found that the mRNA expression of 332 
ICAM1 and VCAM1 was enhanced in NPs with eLTs compared with controls or NPs 333 
without eLTs (Fig 4, A). Although ICAM1 and VCAM1 positive vessels were 334 
distributed throughout lamina propria of nasal tissues (Fig E7), their expression was 335 
enriched in polyp eLTs in areas where HEVs were observed (Fig 4, D). 336 
 337 
Polyp eLTs correlated to local production of IgG, IgE, and IgA but not IgM  338 
Given the hyperproduction of several Ig isotypes in NPs, we next tested the 339 
notion that eLTs can support local Ig production. T follicular helper (TFH) cells in 340 
GCs regulate B cell somatic hypermutation and provide B cells with necessary signals 341 
for Ig isotype switching and memory formation.35 TFH cells up-regulate the 342 
expression of CXCR5, inducible costimulator (ICOS), programmed cell death protein 343 
(PD1), transcription factor Bcl-6, and IL-21 to enable their function.35 Consistent with 344 
our previous report,15 CXCR5+CD4+ TFH cells were identified in B-cell areas in 345 
polyp eLTs (Fig 5，A). Using flow cytometry, we further found a similar increase of 346 
frequencies of total TFH cells, ICOS+ TFH cells, PD-1+ TFH cells, ICOS+PD-1+ TFH 347 
cells, and IL-21+ TFH cells in NMCs from eosinophilic and non-eosinophilic NPs 348 
with eLTs in comparison with those from NPs without eLTs and controls (Fig 5, B). 349 
Notably, the expression of ICOSL and IL-21 was up-regulated in TFH cells from NPs 350 
with eLTs compared with those from NPs without eLTs and control mucosa, 351 
suggesting an increased activity of TFH cells in polyp eLTs (Fig E8).  352 
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Moreover, we found that NPs with eLTs had higher mRNA levels of 353 
activation-induced cytidine deaminase (AID, an enzyme required for somatic 354 
hypermutation and isotype class-switch of GC B cells), CD21L (a marker for FDC), 355 
and B-cell activating factor of the tumor necrosis factor family (BAFF, a B-cell 356 
survival promoting factor) than NPs without eLTs and controls (Fig 5, C). There were 357 
positive correlations between CD21L and BAFF, CD21L and AID, and BAFF and 358 
AID expression in polyps with eLTs (Fig E9), suggesting a potential role of BAFF and 359 
FDC on AID expression and Ig class switch in B cells. By immunohistochemical 360 
staining, we confirmed the predominant expression of AID and BAFF in follicles of 361 
polyp eLTs (Fig 5, D). CD23 is required for the survival and differentiation of GC B 362 
cells. CD23+ B cells and FDCs in polyp eLTs were demonstrated by 363 
immunofluorescence (Fig 5, E). Consistent with up-regulated IL-7 and BAFF signals 364 
in polyp eLTs, we observed Bcl-2+ cells in the periphery of follicles of polyp eLTs 365 
(Fig 5, D).  366 
After defining the presence of cellular and molecular components required for Ig 367 
class switching in polyp eLTs, we explored the potential function of eLTs in local Ig 368 
production in polyps. Consistent with our previous report,15 we found that IgE levels 369 
were increased in eosinophilic NPs, and IgA and IgG levels were up-regulated in both 370 
eosinophilic and non-eosinophilic NPs, in comparison with controls, while IgM levels 371 
were comparable (Fig E10). Importantly, we found that IgE levels were prominently 372 
increased in eosinophilic NPs, and total IgG and IgA levels were up-regulated in both 373 
eosinophilic and non-eosinophilic NPs with eLTs compared with those without eLTs, 374 
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respectively (Fig 6, A). Compared with controls, no increase of IgM levels was found 375 
in polyps with or without eLTs (Fig 6, A), suggesting that eLTs are more essential for 376 
the production of isotype class-switched antibodies. Immunofluorescence showed that 377 
IgM was mainly expressed by CD20+ B cells but not plasma cells in eLTs, suggesting 378 
that IgM+ cells are potentially IgM+ unswitched B cells (Fig 6, B). In contrast, IgE+, 379 
IgA+, and IgG+ plasma cells were readily detected, and a few IgE+, IgA+, and IgG+ B 380 
cells were found in polyp eLTs (Fig 6, B). In addition, IgE staining was also 381 
co-localized with some DCs, FDCs, and tryptase+ mast cells (Fig 6, C).  382 
In order to gain direct evidence that polyp eLTs support local Ig production, we 383 
performed an ex vivo challenge assay. After the ex vivo stimulation with Der p1, the 384 
specific circle transcript of Iε-Cµ (408 bp) produced during class-switch 385 
recombination from IgM to IgE was detected in 4 of 5 eosinophilic NPs with local 386 
sIgE against Der p1 and eLTs (Fig 6, D). Iε-Cµ circle transcript was also detected in 1 387 
non-stimulated eosinophilic NP with eLTs. However, no Iε-Cµ circle transcript was 388 
detected in 4 eosinophilic NPs having local sIgE against Der p1 but without eLTs 389 
before or after stimulation. For 8 non-eosinophilic NPs without local sIgE against Der 390 
p1, no Iε-Cµ circle transcript was detected regardless of the presence of eLTs. No 391 
Iε-Cµ circle transcript was detected in 5 controls either (Table E11). No Iε-Cγ circle 392 
transcript (339 bp) produced from any subclass of IgG to IgE, or Iε-Cγ1, Iε-Cγ3 or 393 
Iε-Cγ4 circle transcript (339 bp) produced from specific IgG subclass to IgE was 394 
detected in any samples (Table E11). After stimulation, protein levels of IL-4, IL-5, 395 
IL-13, and IL-17A in the supernatant were significantly increased in eosinophilic NPs 396 
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with eLTs, but not in eosinophilic NP without eLTs or controls (Fig E11). In contrast, 397 
for non-eosinophilic NPs, no significant change of those cytokines was found after 398 
stimulation regardless of the presence of eLTs (Fig E12). 399 
 400 
The formation of eLTs associated with disease severity 401 
Finally, we examined the association between eLT formation and objective CRS 402 
severity, symptom severity, disease duration, prior surgery, asthma, and allergic 403 
rhinitis, and we found longer disease duration, more severe nasal obstruction, and 404 
higher frequency of prior surgery in patients with eLTs compared with those without 405 
eLTs (Table E12).  406 
 407 
DISCUSSION 408 
Although the infiltration of immune cells and the formation of lymphoid 409 
aggregates have been reported in NPs, the characteristics of lymphoid aggregates, 410 
immunological mechanism for the formation, and their functions have not been well 411 
determined. This is the first study that demonstrates the presence of lymphoid 412 
aggregates with different sizes and features in over half of both eosinophilic and 413 
non-eosinophilic NPs. The simultaneous presence of lymphoid aggregates in various 414 
grades reflects a dynamic process of lymphoid neogenesis in NPs (Fig E1). Larger 415 
lymphoid aggregates demonstrated relatively well-developed structures (Table 1). The 416 
majority of grade 2 and grade 3 aggregates developed into eLTs. The eLTs were found 417 
in about 20% of CRSwNP patients but were almost absent in controls and CRSsNP 418 
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patients (Fig 2). A very recent study demonstrated the presence of eLTs in 37% of 419 
polyps but in none of normal ethmoid mucosa, slightly higher than our results.16 This 420 
might be due to less stringent criteria using hematoxylin-eosin staining,16 as compared 421 
to a more comprehensive validation by immunohistochemistry in our study. A similar 422 
finding of increased formation of lymphoid structures in polyps was also reported by 423 
Shinoda et al.36 In contrast, Feldman et al. did not show a difference in B cell follicles 424 
or B cell clusters in polyps compared to normal ethmoid tissues.37 The reasons for 425 
those discrepancies are unclear currently; however, Feldman et al. did not investigate 426 
the structures of follicles in detail, including the presence of HEVs and FDCs.37 Here, 427 
we did not find a difference in the frequency of eLT formation between eosinophilic 428 
and non-eosinophilic NPs, suggesting that multiple up-stream factors can initiate eLT 429 
formation in chronically inflamed tissues. The formation of lymphoid aggregates in 430 
NPs is unlikely due to the co-existence of allergic rhinitis and asthma, since CRSwNP 431 
patients without allergic rhinitis and asthma also demonstrated a significantly higher 432 
frequency of lymphoid aggregates compared with controls (data not shown).  433 
The expression of eLT related genes in CRSwNP has been investigated 434 
previously,10, 16 but the association between the expression of those genes and 435 
formation of eLTs remains undetermined. Our study for the first time revealed a 436 
significant association between eLT formation, expression of homeostatic chemokines 437 
and chemokine receptors, and up-stream lymphorganogenic signaling pathways in 438 
CRSwNP (Figs 3 and 4). Interestingly, although previous studies demonstrated 439 
different immunological conditions in eosinophilic and non-eosinophilic NPs,17 we 440 
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found that they shared similar lymphoid neogenesis and compartmentalization 441 
pathways in the development of eLTs (Figs 3 and 4). It suggests that different disease 442 
initiators may activate similar downstream lymphoid neogenesis pathways in 443 
eosinophilic and non-eosinophilic polyps. In fact, IL-17, CXCL13, and LT are 444 
similarly implicated in the development of eLTs in different diseases and 445 
inflammatory conditions including autoimmune diseases, chronic obstructive 446 
pulmonary disease, and pulmonary inflammation induced by bacteria and viruses.38-41 447 
However, the relative contributions of each individual molecule and their 448 
inter-regulation in the formation of polyp eLTs are topics to be studied in the future. It 449 
should be noted that expression of those molecules was also found in other areas of 450 
polyps besides eLTs (Figs E4-E7), suggesting additional functions beyond eLT 451 
formation for those molecules in the pathogenesis of NPs.20, 34, 36, 42-45 Type 17 452 
response was absent in tissue samples from European and North American patients 453 
with polyps in contrast to Chinese patients with polyps.23, 46, 47 On the other hand, 454 
IL-17 was highly detected in CRSsNP where no up-regulation of eLT formation was 455 
found.23, 47 Therefore, the role of IL-17 in the development of eLTs in NPs requires 456 
further investigation.  457 
In regards to the previously unknown function of polyp eLTs, our study provides 458 
several lines of novel evidence for the regulatory role of eLTs in local Ig production 459 
in NPs. First, we identified the presence of cellular and molecular elements essential 460 
for B cell differentiation and activation as well as in situ antibody diversification and 461 
isotype switching in polyp eLTs, including TFH cells, AID, BAFF, and CD23. The 462 
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expression levels of those cellular and molecular components were related to the 463 
presence of eLTs in NPs (Fig 5). Second, we found that local hyperproduction of IgE, 464 
IgG, and IgA was more prominent in NPs with eLTs than that in NPs without eLTs 465 
(Fig 6, A). In addition, IgA, IgG, and IgE-producing plasma cells could be detected in 466 
polyp eLTs, confirming the local Ig production in polyp eLTs (Fig 6, B). Third, most 467 
importantly, we demonstrated ongoing Ig class-switch recombination to IgE only in 468 
eosinophilic polyps with eLTs, but not in those without eLTs after ex vivo stimulation 469 
with specific allergens (Fig 6, D and Table E11). The ex vivo tissue challenge assay 470 
allowed us to confirm the intrinsic origin of Ig production of eLTs. In this study, we 471 
failed to observe clear expression of Iε-Cγ circle transcript after stimulation, 472 
disfavoring the sequential switching to IgE through IgG in NPs. Stimulation with 473 
specific antigen also led to production of IL-4 and IL-13 in eosinophilic NPs with 474 
eLTs, which are strong inducers of IgE switch.25, 27 In polyps without eLTs, we also 475 
detected enhanced levels of IgE, IgG, and IgA compared with controls. It is possible 476 
that B cells already committed to Ig synthesis in secondary lymphoid organs are 477 
recruited to the inflamed NPs and contribute to local Ig production. We cannot rule 478 
out the possibility that Igs produced in secondary lymphoid organs circulate to NPs 479 
either. Nevertheless, our findings clearly demonstrate an important contribution of 480 
eLTs to local Ig in NPs. In this study, we found that IgE was only up-regulated in 481 
eosinophilic NPs with eLTs, suggesting that distinct external pathogenic stimulators 482 
and intrinsic responses would determine the function of eLTs in subjects with different 483 
types of CRSwNP. The pathological role of local IgE in the eosinophilic inflammation 484 
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in NPs has been revealed by several previous studies.5, 11, 14, 15 However, the antigen 485 
specificity of IgG and IgA and their roles in the pathogenesis of NPs are poorly 486 
understood and deserve more studies in the future.6-8  487 
Based on this prospective study with large sample size, we found that eLT 488 
formation was associated with a higher frequency of prior surgery, suggesting that 489 
eLTs may affect disease progression. One limitation of our study is to use inferior 490 
turbinate mucosal samples as controls for NPs. However, the limited amount of 491 
ethmoid tissues does not allow us to perform extensive studies. In fact, we did not 492 
find significant formation of lymphoid aggregates, especially eLTs, in normal ethmoid 493 
mucosal samples with a small sample size (Fig E13). Another limitation is that we did 494 
not investigate the production of different IgG subclasses. Clearly, different IgG 495 
subclasses may have distinct functions, and this study is currently in progress in our 496 
lab. 497 
In conclusion, NPs have up-regulated formation of eLTs under chronic 498 
inflammation. Homeostatic chemokines, LTβR signaling, and survival factors are 499 
involved in the development of eLTs in both eosinophilic and non-eosinophilic NPs. 500 
Polyp eLTs support local Ig production and contribute to disease progression of NPs 501 
(Fig 7). Despite the limits inherent to studies in humans, in this study, we provided 502 
novel insights into the formation and function of eLTs in NPs and underscored that 503 
eLTs might be a potential therapeutic target to control inflammation in CRSwNP. It 504 
would be interesting to investigate whether steroids diminish the formation of eLTs in 505 
CRSwNP patients.  506 
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Table 1. Structures of lymphoid aggregates in nasal polyps 704 
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  Number 
of 
samples 
analyzed 
T/B 
segregation, 
n (%) 
PNAd+ 
HEV,        
n (%) 
CXCL13,    
n (%) 
CCL21,      
n (%) 
CD21,        
n (%) 
Ki-67,      
n (%) 
 ENP 18 5 3 2 2 0 0 
Grade 1   (27.77%) (16.67%) (11.11%) (11.11%) (0%) (0%) 
 NENP 14 3 2 1 1 0 0 
   (21.42%) (14.29%) (7.14%) (7.14%) (0%) (0%) 
 ENP 6 4 5 6 6 3 5 
Grade 2   (66.67%) (83.33%) (100%) (100%) (50%) (83.33%) 
 NENP 8 6 6 7 7 6 6 
   (75%) (75%) (87.5%) (87.5%) (75%) (75%) 
 ENP 8 7 8 8 8 7 8 
Grade 3   (87.5%) (100%) (100%) (100%) (87.5%) (100%) 
 NENP 5 5 5 5 5 5 5 
   (100%) (100%) (100%) (100%) (100%) (100%) 
Grade corresponds to the highest grade of lymphoid aggregation present in a nasal 706 
polyp sample. 707 
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Figure 1. Structures of eLTs in nasal polyps. A, (a) Representative photomicrographs 720 
showing consecutive tissue sections stained for CD3+ T cells, CD20+ B cells, CD21+ 721 
follicular DCs, and Ki-67+ proliferating cells. Original magnification × 100; (b) 722 
Higher magnification of the outlined area of (a). B, (a) Representative 723 
photomicrographs showing PNAd+ HEVs, D2-40+ lymphatic vessels, CD11c+ 724 
myeloid DCs (mDCs), CD138+ plasma cells, CD68+ macrophages, and CD56+ nature 725 
killer cells. Original magnification × 200; (b) Higher magnification of the outlined 726 
area of (a). C, Representative photomicrographs showing Ki-67+ B cells in polyp eLTs. 727 
Original magnification × 200. Arrows denote Ki-67+ B cells. D, Localization of 728 
mDCs in eLTs. Representative photomicrographs showing consecutive tissue sections 729 
stained for CD3 and CD11c, and CD3 and CD20. Original magnification × 200. 730 
Arrow denotes close contact between T cells and mDCs. In (C) and (D), insets show a 731 
higher magnification of the outlined area.  732 
 733 
Figure 2. Increased formation of eLTs in NPs.  734 
 735 
Figure 3. Increased expression of homeostatic chemokines and chemokine receptors 736 
in NPs with eLTs. A, The mRNA levels of homeostatic chemokines and chemokine 737 
receptors. eLTs-, without eLTs; eLTs+, with eLTs. *P < 0.05; **P < 0.01; ***P < 738 
0.001. B, Representative photomicrographs showing staining for CXCL13 and CD21, 739 
and CXCL13 and CD20 in polyp eLTs. Original magnification × 200. C, (a) 740 
Representative photomicrographs showing staining for CCL21 in polyp eLTs. 741 
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Original magnification × 100; (b) Higher magnification of the outlined area of (a). D, 742 
Representative photomicrographs showing staining for CXCR5 and CD20, and CCR7 743 
and CD3 in polyp eLTs. Original magnification × 200. In (B) and (D), insets show a 744 
higher magnification of the outlined area and arrows denote positive cells. 745 
  746 
Figure 4. Increased expression of lymphorganogenic factors and adhesion molecules 747 
in NPs with eLTs. A, The mRNA levels of lymphorganogenic factors and adhesion 748 
molecules. eLTs-, without eLTs; eLTs+, with eLTs. *P < 0.05; **P < 0.01; ***P < 749 
0.001. B, (a) Representative photomicrographs showing polyp tissue sections stained 750 
for LTα, LTβ and LTβR. Original magnification × 100; (b) Higher magnification of 751 
the outlined area of (a). C and D, Representative photomicrographs showing staining 752 
for (C) LTβR and CD20, IL-17A, and IL-7, and (D) VCAM1 and ICAM1 in polyp 753 
eLTs. Original magnification × 200. Insets show a higher magnification of the 754 
outlined area. Arrows denote positive cells. 755 
 756 
Figure 5. Presence of cellular and molecular components required for 757 
immunoglobulin production in eLTs in NPs. A, Identification of CXCR5+CD4+ TFH 758 
cells in B-cell follicles of polyp eLTs. Representative photomicrographs showing the 759 
staining of consecutive sections. Original magnification × 200. B, (a) Gating strategy 760 
and representative flow plots; (b) The frequencies of different types of cells in nasal 761 
mucosal mononuclear cells (NMCs) or in CD4+ T cells; (c) The percentages of TFH 762 
cell subsets in NMCs. C, The mRNA expression levels of AID, CD21L, and BAFF. 763 
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eLTs-, without eLTs; eLTs+, with eLTs. *P < 0.05; **P < 0.01; ***P < 0.001. D, (a) 764 
Representative photomicrographs showing the staining for AID, BAFF, and Bcl-2. 765 
Original magnification × 200; (b) Higher magnification of the outline area of (a). E, 766 
Representative photomicrographs showing staining for CD23 and CD20, and CD23 767 
and CD21. Original magnification × 200. In (A) and (E), insets show a higher 768 
magnification of the outlined area and arrows denote positive cells. 769 
 770 
Figure 6. Increased local immunoglobulin production in NPs with eLTs. A, The local 771 
protein levels of immunoglobulins. B, Representative photomicrographs showing 772 
staining for immunoglobulins, CD20, and CD138. Original magnification × 200. C, 773 
Representative photomicrographs showing staining for IgE, CD21, and tryptase. 774 
Original magnification × 200. In (B) and (C), insets show a higher magnification of 775 
the outlined area and arrows denote positive cells. D, Representative pictures of 776 
electrophoresis results of semi-nested PCR assay of specific circle transcript of Iε-Cµ 777 
(408 bp) in polyp tissues following ex vivo Der p1 challenge. Lanes M, +C, -C 778 
correspond to marker, PCR positive control, and negative control. PCR amplification 779 
of mRNA isolated from tonsil B cells stimulated with IL-4 and soluble CD40L was 780 
used as positive control. A ‘no template’ sample was used as negative control. eLTs-, 781 
without eLTs; eLTs+, with eLTs. *P < 0.05; **P < 0.01; ***P < 0.001. 782 
 783 
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Figure 7. Schematic overview of histological structure and immunoglobulin 784 
production supporting function of eLT in NPs, and potential mechanisms underlying 785 
lymphoid neogenesis in NPs. 786 
 787 
 788 
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METHODS 45 
Subjects and specimens 46 
This study was approved by the Ethics Committee of Tongji Hospital of 47 
Huazhong University of Science and Technology and was conducted with written 48 
informed consent from each patient. A total of 103 patients with eosinophilic chronic 49 
rhinosinusitis with nasal polyps (CRSwNP), 171 patients with non-eosinophilic 50 
CRSwNP, 53 patients with chronic rhinosinusitis without nasal polyps (CRSsNP), and 51 
135 subjects undergoing septoplasty without other sinonasal diseases were included in 52 
this study. Atopic status was evaluated by skin prick test to a standard panel of 16 53 
aeroallergens in our region that was performed in accordance with WHO guideline.E1, 54 
E2
 Allergic rhinitis was diagnosed based on the concordance between a typical history 55 
of allergic symptoms and positive atopy test.E3 The diagnosis of asthma was based on 56 
Global Initiative for Asthma guideline.E4 Oral glucocorticoids and intranasal steroid 57 
sprays were discontinued at least 3 months and 1 month before surgery, respectively. 58 
None had received anti-leukotrienes or immunotherapy. Subjects who had an 59 
antrochoanal polyp, cystic fibrosis, fungal sinusitis, primary ciliary dyskinesia, 60 
vasculitis, or an acute upper respiratory tract infection within 1 month of entering the 61 
study were excluded from the study. Computed tomography (CT) scans in the axial 62 
and coronal plane were obtained preoperatively and evaluated by using the 63 
Lund-Mackay CT scoring system as previously described.E5 Subjective symptoms 64 
focused on nasal obstruction, rhinorrhea, loss of sense of smell, facial pain, and 65 
headache were scored on a visual analogue scale (VAS) of 0 to 10 as previously 66 
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described.E5 The total VAS symptom scores were calculated based on the sum of these 67 
five VAS symptom domains. The overall disease burden was also scored on a VAS by 68 
asking patients how troublesome their disease was in affecting their daily activity and 69 
sleep.E5 Endoscopy physical findings were scored according to Lanza and Kennedy.E5 70 
Polyp tissues from CRSwNP patients, diseased sinus mucosa from CRSsNP 71 
patients, and inferior turbinate mucosa from control subjects were collected during 72 
surgery. Given the limited amount of tissue samples, not all samples were included in 73 
every study protocol. The demographic characteristics of CRSwNP and control 74 
subjects are summarized in Table E1. For CRSsNP patients, age (years) median was 75 
36 (interquartile ranges, 24-55) and 37 (70%) of them were male. There were 9 atopic 76 
patients (17%), 5 (9%) patients with asthma, and 6 (11%) patients with allergic 77 
rhinitis in CRSsNP patient group. 78 
 79 
Histology study 80 
For each subject, 2-5 paraffin blocks of a sinonasal mucosal sample were 81 
randomly chosen. At least three sections (4 µm) from the anterior, middle and 82 
posterior portion of paraffin blocks were obtained for histology study. Sections were 83 
stained with hematoxylin-eosin to screen the presence of lymphoid aggregates by two 84 
independent investigators. In the case of disagreement, a consensus was reached by 85 
reviewing the specimen at a multi-head microscope by these two investigators.E6 86 
Aggregates featuring a global count of less than 15 cells were not considered.E7 87 
Lymphocyte aggregation was graded according to a previously described method.E7,  88 
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E8
 Each sample was graded according to the highest level of lymphoid aggregation 89 
present.E7, E8 Cell aggregates with a radial cell count between 2 and 5 cells are 90 
classified as Grade 1.E7, E8 Grade 2 aggregates have a radial cell count from 6 to 10 91 
cells, while Grade 3 aggregates have more than 10 radial cells.E7, E8 The radial cell 92 
count was estimated by counting the number of cells from the central point to the 93 
identifiable edge of each aggregate with the widest infiltration (Fig E1, A).E7 The 94 
number of lymphoid aggregates was counted at a low power magnification (× 100), 95 
and 5 low power fields (LPFs) were randomly selected and analyzed. 96 
 97 
Immunohistochemistry and immunofluorescence 98 
After screening the presence of lymphoid aggregates in tissues by 99 
hematoxylin-eosin staining, additional adjacent tissue sections were prepared for 100 
immunohistochemical and immunofluorescence staining. Immunohistochemistry and 101 
immunofluorescence were performed as previously described.E6, E9-11After 102 
deparaffinization and rehydration, sections were subjected to heat-induced antigen 103 
retrieval using Target Retrieval Solution (Dako, Carpinteria, Calif, USA). The 5% 104 
bovine serum albumin was used to block nonspecific binding. Primary antibodies 105 
used are listed in Table E2. Fluorescence conjugated secondary antibodies used are 106 
listed in Table E3. For immunohistochemical staining, the 107 
streptavidin-biotin-peroxidase complex detecting method (Boster Biotechnology, 108 
Wuhan, China) was employed and color development was achieved with 3’, 109 
3’-diaminobenzidine.E6, E9 Structures of lymphoid aggregates were evaluated by 110 
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staining sections for CD3, CD20, CD21, CD23, CD11c, CD138, CD68, CD56, Ki-67, 111 
B-cell lymphoma 2 (Bcl-2), activation-induced cytidine deaminase (AID), peripheral 112 
node addressin (PNAd), and D2-40. In addition, the expression of lymphorganogenic 113 
factors including chemokine (C-X-C motif) ligand 13 (CXCL13)/C-X-C chemokine 114 
receptor 5 (CXCR5), chemokine (C-C motif) ligand 21 (CCL21)/C-C chemokine 115 
receptor 7 (CCR7), lymphotoxin α (LTα), lymphotoxin β (LTβ), LTβ receptor (LTβR), 116 
B cell-activating factor of the tumor necrosis factor family (BAFF), IL-17A, IL-7, 117 
intercellular adhesion molecule 1 (ICAM1), and vascular cell adhesion molecule 1 118 
(VCAM1) as well as the immunoglobulin (Ig) positive cells including IgE-, IgA-, 119 
IgG-, and IgM-expressing cells were assessed by immunohistochemistry and 120 
immunofluorescence. Germinal center (GC)-like structures were defined as T and B 121 
cell aggregates with Ki-67+ proliferating B cells, a network of CD21+ follicular 122 
dendritic cells (FDCs), and development of high endothelial venules (HEVs).E12 123 
Human tonsil tissues were used as positive controls for immunohistochemistry and 124 
immunofluorescence (Fig E2). Images were recorded with PS software (Photoshop, 125 
Adobe systems, San Jose, California, USA). Species and subtype-matched antibodies 126 
were used as negative controls. 127 
 128 
Measurement of Igs and cytokines  129 
Tissue samples were weighted and homogenized, and the supernatants were 130 
harvested.E13 The protein levels of IgA, IgG, and IgM in tissue homogenates were 131 
detected by means of Bio-Plex suspension chip technology (BIO-RAD, Hercules, CA, 132 
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USA),E13 and the lower detection limits are listed in Table E4. Tissue total IgE and 133 
specific IgE to Dermatophagoides pteronyssinus group 1 (Der p1) were detected by 134 
using ImmunoCAP system (Phadia, Uppsala, Sweden) as previously reported.E14, E15 135 
The lower detection limit for IgE was 0.35 kU/L. An ELISA-based chemiluminescent 136 
custom-made Q-Plex Custom array (Quansys Bioscience, West Logan, UT, USA) was 137 
used to detect the levels of various cytokines in supernatants of tissue explant 138 
culture,E16 and the lower detection limits are listed in Table E5. Tissue CXCL13, 139 
CCL21, and lymphotoxin α (LTα) were detected by using ELISA (MultiSciences, 140 
Hanzhou, China) following the instructions of manufacturer,E17 and the lower 141 
detection limits are listed in Table E6. The levels of IgA, IgG, IgM, CXCL13, CCL21, 142 
and LTα in tissues were normalized to total tissue protein levels quantified by using a 143 
BCA protein detection kit (Guge Biotechnology, Wuhan, China).E13, E18  144 
 145 
Reverse transcription polymerase chain reaction 146 
As mentioned elsewhere,E6, E14 total RNA was extracted by using TRIzol 147 
(Invitrogen Life Technologies, Carlsbad, California, USA) and reverse-transcribed to 148 
cDNA by using a PrimeScript RT reagent kit (TaKaRa Biotechnology, Dalian, China). 149 
Real-time PCR was carried out using SYBR Premix Ex Taq kit (TaKaRa 150 
Biotechnology, Dalian, China) with appropriate primers (Table E7) on Light-Cycler 151 
system (Roche Diagnostics, Mannheim, Germany). Relative gene expression was 152 
calculated by using 2(-Delta Delta CT) method.E6, E14 An inferior turbinate sample 153 
from a control subject was used as a calibrator. Glucuronidase-β (GUSB) or β-actin 154 
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was used as a housekeeping gene for normalization and a ‘no template’ sample was 155 
used as negative control. As previously described, the specific circle transcripts, Iε-Cµ 156 
(product resulting from class-switch recombination from IgM to IgE) and Iε-Cγ 157 
(product resulting from any IgG subclass to IgE) as well as Iε-Cγ1, Iε-Cγ3 and Iε-Cγ4 158 
(products resulting from specific IgG subclass to IgE), were detected using 159 
semi-nested PCR amplification protocol with appropriate primers (Table E8).E14 The 160 
first cycle was conducted at 94 ºC for 5 min, followed by 40 cycles of 94 ºC for 1 min, 161 
66 ºC for 1 min, and 72 ºC for 1 min. The second round PCR was performed on a 5 162 
µL aliquot of the first round PCR product with the same condition as mentioned above, 163 
except for the annealing temperature of 60 ºC. For each sample cDNA equivalent to 164 
40 ng of total RNA was used. PCR amplification of mRNA isolated from tonsil B 165 
cells stimulated with IL-4 (200 U/mL, R&D systems, Minneapolis, Minn, USA) and 166 
soluble CD40L (0.1 µg/mL, R&D) for 5 days was used as positive control for circle 167 
transcript expression. A ‘no template’ sample was used as negative control. The 168 
semi-nested PCR products were subjected to agarose gel electrophoresis and 169 
visualized by ultraviolet transillumination. 170 
 171 
Ex vivo allergen challenge  172 
Sinonasal mucosal samples were used for ex vivo air-liquid interface culture as 173 
described previously.E19 Sections of tissues of approximately 6 mm3 were placed on 174 
0.4-µm well inserts (Millipore Corp., Billerica, MA, USA) in 2 mL of Dulbecco’s 175 
modified Eagle’s medium/F-12 supplemented with 2 mM glutamine, 100 U/mL 176 
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penicillin, and 100 µg/mL streptomycin (Invitrogen, Carlsbad, CA, USA). The tissue 177 
samples were oriented with the epithelium being exposed to the air, forming an 178 
air-liquid interface to mimic the in vivo situation. Following the previously described 179 
method,E19, E20 the tissues were stimulated with recombinant Der p1 (20 µg/mL; 180 
endotoxin ≤ 0.03 EU/µg; Indoor Biotechnologies, Charlottesville, VA, USA) and 181 
cultured at 37 °C with 5% CO2 in humidified air for 24 hours. After culture, tissues 182 
and supernatants were harvested for semi-nested PCR and ELISA  analysis, 183 
respectively. 184 
 185 
Flow cytometry 186 
Sinonasal mucosal samples were dissociated mechanically with the 187 
GentleMACS Dissociator (Miltenyi Biotec Technology & Trading (Shanghai) Co. 188 
Shanghai, China).E13 The resulting cell suspension was filtered through a mesh of 40 189 
µm twice and then the nasal mucosal mononuclear cells (NMCs) were isolated by 190 
density-gradient centrifugation on Lymphoprep (AXIS-SHIELD PoC AS, Oslo, 191 
Norway) as previously described.E9, E13 The viability of generated NMCs was greater 192 
than 97% as detected by propidium iodide (MultiSciences Biotech, Hangzhou, China) 193 
staining.E13  Lymphocytes were defined, and debris, dead cells, and aggregates were 194 
excluded, by forward angle and side scatter gating. Cells were surface stained for 195 
CD4, inducible costimulator (ICOS), programmed cell death protein (PD1), and 196 
CXCR5 with specific antibodies at 4°C for 30 minutes.E13 For intracellular IL-21 197 
staining, NMCs were cultured in the presence of Cell Stimulation Cocktail containing 198 
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protein transport inhibitors (eBioscience, San Diego, CA, USA) in RPMI 1640 199 
medium (Invitrogen Life Technologies, Carlsbad, CA, USA) at 37°C for 12 hours and 200 
then fixed and permeabilized with Cytofix/Cytoperm Kit (Invitrogen Life 201 
Technologies). After that, cells were stained with mouse monoclonal antibodies 202 
against IL-21.E13 Species and subtype-matched antibodies were used as controls. FH 203 
cells were identified as CXCR5+CD4+ cells. In gated TFH cells, the expression of 204 
PD1, ICOS and IL-21 was analyzed. The primary antibodies used are listed in Table 205 
E9. The stained cells were analyzed on a FACS Calibur flow cytometer (Beckton 206 
Dickinson, San Jose, CA, USA) and data were analyzed using FlowJo software 207 
(TreeStar, Ashland, OR, USA). 208 
 209 
 210 
 211 
 212 
 213 
 214 
 215 
 216 
 217 
 218 
 219 
 220 
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Table E1. Demographic characteristics of enrolled subjects  328 
 Control ENP NENP 
Control vs 
ENP 
Control vs 
NENP 
ENP vs 
NENP 
    
P value P value P value 
Total subjects enrolled 135 103 171    
Methodology used        
Histology study       
Subject number 135 96 168 
   
Gender, male 100 (74%) 70 (73%) 101 (60%) 0.844 0.011 0.036 
Age (years) 32 (23, 49) 43 (30, 56) 37 (20, 50) 0.058 0.715 0.122 
Patients with atopy 18 (13%) 27 (28%) 32 (19%) 0.005 0.183 0.089 
Patients with AR 0 (0) 20 (21%) 29 (17%) < 0.001 < 0.001 0.473 
Patients with asthma 0 (0) 16 (17%) 7 (4%) < 0.001 0.018 0.001 
Immunohistochemistry and 
immunofluorescence 
   
  
 
Subject number 54 58 52    
Gender, male 41 (76%) 43 (74%) 37 (71%) 0.827 0.578 0.726 
Age (years) 30 (21, 49) 38 (25, 51) 36 (20, 49) 0.079 0.211 0.658 
Patients with atopy 10 (19%) 14 (24%) 9 (17%) 0.468 0.871 0.379 
Patients with AR 0 (0) 8 (14%) 7 (13%) 0.006 0.006 0.960 
Patients with asthma 0 (0) 6 (10%) 3 (6%) 0.028 0.115 0.495 
RT-PCR       
Subject number 12 26 23    
Gender, male 8 (67%) 18 (69%) 18 (78%) 1.000 0.686 0.475 
Age (years) 24 (19, 42) 37 (23, 54) 35 (20, 51) 0.071 0.055 0.755 
Patients with atopy 1 (8%) 7 (27%) 4 (17%) 0.393 0.640 0.425 
Patients with AR 0 (0) 3 (12%) 3 (13%) 0.538 0.536 1.000 
Patients with asthma 0 (0) 3 (12%) 1 (4%) 0.538 1.000 0.612 
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Flow cytometry       
Subject number 22 28 24    
Gender, male 15 (68%) 22 (79%) 17 (71%) 0.406 0.845 0.521 
Age (years) 29 (18, 49) 39 (19, 62) 37 (20, 61) 0.092 0.098 0.993 
Patients with atopy 4 (18%) 7 (25%) 5 (21%) 0.734 1.000 0.722 
Patients with AR 0 (0) 7 (25%) 3 (13%) 0.014 0.235 0.254 
Patients with asthma 0 (0) 1 (4%) 0 (0%) 1.000 - 1.000 
Immunoglobulin 
measurement 
   
  
 
Subject number 16 38 43    
Gender, male 12 (75%) 29 (76%) 25 (58%) 1.000 0.234 0.083 
Age (years) 31 (22, 56) 43 (27, 59) 41 (22, 62) 0.125 0.122 0.508 
Patients with atopy 2 (13%) 12 (32%) 9 (21%) 0.187 0.710 0.275 
Patients with AR 0 (0) 6 (16%) 6 (14%) 0.163 0.176 0.816 
Patients with asthma 0 (0) 4 (11%) 3 (7%) 0.306 0.556 0.701 
Ex vivo study       
Subject number 5 9 8    
Gender, male 3 (60%) 6 (67%) 5 (63%)  1.000 1.000 1.000 
Age (years) 43 (29, 51) 44 (32, 48) 45.5 (37, 51) 0.894 0.608 0.562 
Patients with atopy 0 (0) 1 (11%) 0 (0) 1.000 - 1.000 
Patients with AR 0 (0) 1 (11%) 0 (0) 1.000 - 1.000 
Patients with asthma 0 (0) 0 (0) 0 (0) - - - 
For continuous variables, results are expressed as medians and interquartile ranges. 329 
Categorical variables are summarized using percentage.  330 
ENP, eosinophilic nasal polyp; NENP, non-eosinophilic nasal polyp; AR, allergic 331 
rhinitis  332 
 333 
 334 
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Table E2. Primary antibodies used in immunohistochemistry and 335 
immunofluorescence  336 
Antibody Application Species Concentration Clone ID Reference  Source 
CD11c IHC, IF Rabbit 1:100 EP1347Y Ab52632 
Abcam (Cambridge, 
MA,UK) 
CD138 IHC, IF Rabbit Undiluted EP201 ZA-0584 
Zhongshan Golden Bridge 
Biotechnology (Beijing,  
China) 
CD138 IF Mouse 1:100 B-A38 Ab34164 Abcam 
CD3 IHC, IF Mouse 1:100 LN10 ZM-0417 
Zhongshan Golden Bridge 
Biotechnology 
CD4 IF Goat 1:100 polyclonal AF-379 
R&D systems (Minneapolis, 
USA) 
CD21 IHC, IF Rabbit Undiluted EP64 ZA-0525 
Zhongshan Golden Bridge 
Biotechnology 
CD68 IHC Mouse Undiluted KP1 ZM-0060 
Zhongshan Golden Bridge 
Biotechnology 
CD56 IHC Rabbit 1:400 polyclonal bs-0736R 
Biosynthesis Biotechnology 
(Beijing, China) 
CD20 IHC, IF Rabbit 1:100 EP7 ZA-0549 
Zhongshan Golden Bridge 
Biotechnology 
CD20 IF Mouse 1:100 L26 ZM-0039 
Zhongshan Golden Bridge 
Biotechnology 
D2-40 IHC Mouse Undiluted D2-40 ZM-0465 
Zhongshan Golden Bridge 
Biotechnology 
CXCL13 IF Goat Undiluted polyclonal ZG-0601 
Zhongshan Golden Bridge 
Biotechnology 
Ki-67 IHC, IF Rabbit 1:100 EP5 ZA-0502 
Zhongshan Golden Bridge 
Biotechnology 
AID IHC Rabbit 1:100 polyclonal Ab59361 Abcam  
LTα IHC Rabbit 1:100 polyclonal HPA007729 
Sigama-Aldrich (St. Louis, 
MO, USA) 
LTβ IHC Rabbit 1:400 polyclonal HPA048884 Sigama-Aldrich 
LTβR IHC, IF Rabbit 1:600 polyclonal GTX12264 
GeneTex (Irvine, Southern 
California, USA) 
CXCR5 IF Mouse 1:100 51505 MAB190 R&D systems 
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CCR7 IF Rabbit 1:200 polyclonal C3241 Abcam 
IL-7 IF Rabbit 1:100 polyclonal bs-1811R Biosynthesis Biotechnology 
CCL21 IHC Rabbit 1:200 polyclonal bs-1666R Biosynthesis Biotechnology 
CD23 IF Mouse 1:100 UMAB101 ZM-0273 
Zhongshan Golden Bridge 
Biotechnology 
PNAd IHC Rat 1:25 MECA-79 120802 
eBioscience (San Diego, 
Calif, USA) 
Tryptase IF Mouse 1:100 AA1 Ab2378 Abcam 
Bcl-2 IHC Rabbit 1:200 E17 Ab32124 Abcam 
BAFF IHC Rat 1:100 Buffy 2 Ab16081 Abcam 
IL-17A IHC, IF Rabbit 1:100 polyclonal bs-2140R Biosynthesis Biotechnology 
ICAM1 IHC Rabbit 1:200 EP1442Y Ab53013 Abcam 
VCAM1 IHC Rabbit 1:500 EPR5047 Ab134047 Abcam 
IgA IF Rabbit 1:200 EPR5367-76 Ab124716 Abcam 
IgM IF Rabbit 1:100 EPR5539-65-4 Ab134159 Abcam 
IgG IF Rabbit 1:500 RIGG-69 Ab133470 Abcam 
IgE IF Mouse 1:100 B3102E8 9160 
SouthernBiotech 
(Birmingham, USA) 
IgE IF Rabbit Undiluted polyclonal Ab75673 Abcam 
 337 
CXCL13, chemokine (C-X-C motif) ligand 13; AID，?activation-induced cytidine 338 
deaminase; LT, lymphotoxin; LTβR, lymphotoxin beta receptor; CCL21, chemokine 339 
(C-C motif) ligand 21; PNAd, peripheral node addressin; Bcl-2, B cell lymphoma 2; 340 
Ig, immunoglobulin; CXCR5, C-X-C chemokine receptor 5; CCR7, C-C chemokine 341 
receptor 7; IL, interleukin; VCAM1, vascular cell adhesion molecule 1; ICAM1, 342 
intercellular adhesion molecule 1; BAFF, B cell-activating factor of the tumor 343 
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necrosis factor family; Ig, immunoglobulin; IHC, immunohistochemistry; IF, 344 
immunofluorescence. 345 
 346 
 347 
 348 
 349 
 350 
 351 
 352 
 353 
 354 
 355 
 356 
 357 
 358 
 359 
 360 
 361 
 362 
 363 
 364 
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Table E3. Secondary antibodies used in immunofluorescence   366 
Antibody Concentration Clone ID Reference  Source 
IFKine™ Green donkey 
anti-mouse IgG 
1:100 polyclonal A24211 
Abbkine Scientific 
Company (Wuhan,  
China) 
IFKine™ Red donkey 
anti-mouse IgG 
1:100 polyclonal A24411 Abbkine 
IFKine™ Green donkey 
anti-rabbit IgG 
1:100 polyclonal A24221 Abbkine 
IFKine™ Red donkey 
anti-rabbit IgG 
1:100 polyclonal A24421 Abbkine 
IFKine™ Red donkey 
anti-goat IgG 
1:100 polyclonal A24431 Abbkine 
 367 
 368 
 369 
 370 
 371 
 372 
 373 
 374 
 375 
 376 
 377 
 378 
 379 
 380 
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Table E4. Detection limits for Bio-Plex assay.  382 
 383 
Target Detection limit  
IgA 103.4 pg/mL 
IgG 941.0 pg/mL 
IgM 9.0 pg/mL 
Ig, immunoglobulin. 384 
 385 
 386 
 387 
 388 
 389 
 390 
 391 
 392 
 393 
 394 
 395 
 396 
 397 
 398 
 399 
 400 
 401 
 402 
 403 
 404 
 405 
 406 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPTOnline Repository: eLTs in CRSwNP 
22 
 
Table E5. Detection limits for Q-Plex Custom array 407 
 408 
Target Detection limit  
IL-4 2.68 pg/mL 
IL-5 1.90 pg/mL 
IL-7 1.35 pg/mL 
IL-13 3.00 pg/mL 
IL-17A 4.00 pg/mL 
IL-21 1.50 pg/mL 
LTα 0.60 pg/mL 
IL, interleukin; LTα, lymphotoxin α. 409 
 410 
 411 
 412 
 413 
 414 
 415 
 416 
 417 
 418 
 419 
 420 
 421 
 422 
 423 
 424 
 425 
 426 
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Table E6. Detection limits for ELISA 428 
 429 
Target Detection limit  
CXCL13 4.86 pg/mL 
CCL21 2.60 pg/mL 
LTα 2.02 pg/mL 
CXCL13, chemokine (C-X-C motif) ligand 13; CCL21, chemokine (C-C motif) 430 
ligand 21; LTα, lymphotoxin α. 431 
 432 
 433 
 434 
 435 
 436 
 437 
 438 
 439 
 440 
 441 
 442 
 443 
 444 
 445 
 446 
 447 
 448 
 449 
 450 
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Table E7. Primers used for quantitative RT-PCR analysis 452 
Primer Sequence 
Expected 
product size 
(bp) 
Annealing 
temperature 
(°C) 
CXCL12 (F) 5’-ATTCTCAACACTCCAAACTGTGC-3’ 48 60 (R) 5’-CTTCAGCCGGGCTACAATCTG-3’ 
CXCL13 (F) 5’-GGACTCAGAGCTCAAGTCTGAACTC-3’ 78 60 (R) 5’-CAGCAGCATGAGAAGCAGAGA-3’ 
CXCR4 (F) 5’-ACGCCACCAACAGTCAGAG-3’ 96 60 (R) 5’-AGTCGGGAATAGTCAGCAGGA-3’ 
CXCR5 (F) 5’-AACGTCCTGGTGCTGGTGA-3’ 139 60 (R) 5’-CACGGCAAAGGGCAAGA-3’ 
CCL19 (F) 5’-TGTCTGTGACCCAGAAACCCA-3’ 96 60 (R) 5’-TGAACACTACAGCAGGCACCC-3’ 
CCL20 (F) 5’-CTGTACCAAGAGTTTGCTCC-3’ 251 62 (R) 5’-GCACAATATATTTCACCCAAG-3’ 
CCL21 (F) 5’-GCCACACTCTTTCTCCTGCTTT-3’ 109 65 (R) 5’-ACTCTCCCTCCTCGGTCTCTCT-3’ 
CCR6 (F) 5’-TTCAGCGATGTTTTCGACTCC-3’ 134 62 (R) 5’-GCAATCGGTACAAATAGCCTGG-3’ 
CCR7 (F) 5’-TGAGGTCACGGACGATTACAT-3’ 143 60 (R) 5’-GTAGGCCCACGAAACAAATGAT-3’ 
IL-7 (F) 5’-TTGGACTTCCTCCCCTGATCC-3’ 109 60 (R) 5’-TCGATGCTGACCATTAGAACAC-3’ 
IL-7R (F) 5’-CCCTCGTGGAGGTAAAGTGC-3’ 199 60 (R) 5’-CCTTCCCGATAGACGACACTC-3’ 
IL-17A (F) 5’-TCCCACGAAATCCAGGATGC-3’ 75 60 (R) 5’-GGATGTTCAGGTTGACCATCAC-3’ 
IL-17F (F) 5’-GCTGTCGATATTGGGGCTTG-3’ 160 60 (R) 5’-GGAAACGCGCTGGTTTTCAT-3’ 
IL-17RA (F) 5’-GCTTCACCCTGTGGAACGAAT-3’ 98 60 (R) 5’-TATGTGGTGCATGTGCTCAAA-3’ 
VCAM1 (F) 5’-GGGAAGATGGTCGTGATCCTT-3’ 89 60 (R) 5’-TCTGGGGTGGTCTCGATTTTA-3’ 
ICAM1 (F) 5’-ATGCCCAGACATCTGTGTCC-3’ 112 60 (R) 5’-GGGGTCTCTATGCCCAACAA-3’ 
CD21L (F) 5’-TGGAACCTGGGATAAACCTGC-3’ 171 60 (R) 5’-GACTTGTTTCCGTTCATGGAGA-3’ 
AID (F) 5’-GAGGCGTGACAGTGCTACATC-3’ 116 62 (R) 5’-CAGGGTCTAGGTCCCAGTCC-3’ 
BAFF (F) 5’-GGGAGCAGTCACGCCTTAC-3’ 103 60 (R) 5’-GATCGGACAGAGGGGCTTT-3’ 
LTα (F) 5’-ATGACACCACCTGAACGTCTC-3’ 241 60 
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(R) 5’-CTCTCCAGAGCAGTGAGTTCT-3’ 
LTβ (F) 5’-AGGGTGTACGTCAACATCAGTCA-3’ 118 60 (R) 5’-TATTCACGCACTCGCACCA-3’ 
LTβR (F) 5’-AGACCTGCAGGGACCAGGAA-3’ 180 60 (R) 5’-ACAGCTGGCAGATGGTCAGGTA-3’ 
LIGHT (F) 5’-ACTCTACAGTCACACCTATGGCATC -3’ 104 60 (R) 5’-AATCTGGCACTTCGCGTGTA-3’ 
GUSB (F) 5’-GACACGCTAGAGCATGAGGG-3’ 123 60 (R) 5’-GGGTGAGTGTGTTGTTGATGG-3’ 
ACTB (F) 5’-CTGGAACGGTGAAGGTGACA-3’  145 60 (R) 5’-AAGGGACTTCCTGTAACAATGCA-3’        
 453 
CXCL, chemokine (C-X-C motif) ligand; CXCR, C-X-C chemokine receptor; CCL, 454 
chemokine (C-C motif) ligand; CCR, C-C chemokine receptor; IL, interleukin; IL-7R, 455 
interleukin 7 receptor; IL-17RA, interleukin 17 receptor A; VCAM1, vascular cell 456 
adhesion molecule 1; ICAM1, intercellular adhesion molecule 1; LT, lymphotoxin; 457 
LTβR, lymphotoxin β receptor; BAFF, B cell-activating factor of tumor necrosis 458 
factor family; AID, activation-induced cytidine deaminase; CD21L, the long 459 
complement receptor type 2 isoform; LIGHT, tumor necrosis factor superfamily 460 
member 14; GUSB, beta-glucuronidase; ACTB, beta-actin.    461 
 462 
 463 
 464 
 465 
 466 
 467 
 468 
 469 
 470 
 471 
 472 
 473 
 474 
 475 
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Table E8 Primers used for semi-nested PCR analysis  477 
Primer Sequence 
GenBank 
Accession 
No. 
IεF1 5’-GGGAGCTGTCCAGGAACCCGACAGAGC-3’ X56797 
IεF2 5’-GGCCACACATCCACAGGC-3’ X56797 
CµR 5’-GTTGCCGTTGGGGTGCTGG-3’ X17115 
CγR 5’-CCAACTCTCTTGTCCACCTTGG-3’ X04046 
Cγ1R 5’-GGCATGTGTGAGTTTTGTCACAA-3’ J00228 
Cγ3R 5’-GGCACGGGGGAGG-3’ X99549 
Cγ4R 5’-GGGCATGGGGGACCATA-3’ KO1316 
Iε-Cµ transcript was amplified by primer sets IεF1/CµR and IεF2/CµR. Iε-Cγ 478 
transcript was amplified by primer sets IεF1/CγR and IεF2/CγR. Iε-Cγ1, Iε-Cγ3, and 479 
Iε-Cγ4 transcript were amplified by primer sets IεF1/Cγ1R and IεF2/Cγ1R, 480 
IεF1/Cγ3R and IεF2/Cγ3R, and IεF1/Cγ4R and IεF2/Cγ4R, respectively.  481 
 482 
 483 
 484 
 485 
 486 
 487 
 488 
 489 
 490 
 491 
 492 
 493 
 494 
 495 
 496 
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Table E9. Primary antibodies used in flow cytometry   498 
 499 
Antigen-Fluorophore Manufacturer Clone ID Source Isotype Dilution 
CD4-PE 
eBioscience, San 
Diego, CA, USA 
RPA-T4 mouse IgG1, κ 1:20 
CXCR5-Alexa Fluor 
488 
BD PharMingen, San 
Jose, CA, USA 
RF8B2 rat IgG2b, κ 1:20 
ICOS-APC eBioscience ISA-3 mouse IgG1, κ 1:20 
PD1-PerCP/Cy5.5 eBioscience J105 mouse IgG1, κ 1:20 
IL-21-APC 
Biolegend, San Diego, 
CA, USA 
3A3-N2 mouse IgG1, κ 1:20 
PE, phycoerythrin; APC, allophycocyanin; PerCP, peridinin chlorophyll protein 500 
complex; CXCR5, CXCR, C-X-C chemokine receptor 5; ICOS, inducible costimulator; 501 
PD1, programmed cell death protein. 502 
 503 
 504 
 505 
 506 
 507 
 508 
 509 
 510 
 511 
 512 
 513 
 514 
 515 
 516 
 517 
 518 
 519 
 520 
 521 
 522 
 523 
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Table E10. The frequencies of lymphoid aggregates in different study groups 525 
 526 
  
Overall lymphoid 
aggregates, n (%) 
Grade 1, n 
(%) 
Grade 2, n 
(%) 
Grade 3, n 
(%)  
Control (n = 135) 26 (19.26%) 18 (13.33%) 5 (3.70%) 3 (2.22%) 
ENP (n = 96) 52 (54.17%) 32 (33.33%) 10 (10.42%) 10 (10.42%) 
NENP (n = 168) 81 (48.21%) 42 (25.00%) 22 (13.10%) 17 (10.12%) 
ENP, eosinophilic nasal polyps; NENP, non-eosinophilic nasal polyps. 527 
 528 
 529 
 530 
 531 
 532 
 533 
 534 
 535 
 536 
 537 
 538 
 539 
 540 
 541 
 542 
 543 
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Table E11. Detection of circle transcripts in different types of sinonasal tissues 545 
after ex vivo stimulation with Der p1  546 
 Control ENP  NENP 
 local sIgE- 
eLTs- 
n = 5 
local sIgE+ 
eLTs+ 
n = 5 
local sIgE+ 
eLTs-  
n = 4 
 local sIgE- 
eLTs+ 
n = 4 
local sIgE- 
eLTs- 
n = 4 
Iε-Cµ CT 0/5 4/5 0/4  0/4 0/4 
Iε-Cγ, Iε-Cγ1, 
Iε-Cγ3, or 
Iε-Cγ4  CT 
0/5 0/5 0/5  0/5 0/5 
 547 
ENP, eosinophilic nasal polyps; NENP, non-eosinophilic nasal polyps; CT, circle 548 
transcript; sIgE, specific immunoglobulin E against Der p1; eLTs, ectopic lymphoid 549 
tissues. 550 
 551 
 552 
 553 
 554 
 555 
 556 
 557 
 558 
 559 
 560 
 561 
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Table E12. The association between ectopic lymphoid tissue formation and 563 
clinical characteristics in patients with nasal polyps 564 
  NP NP   
 
 eLTs-  eLTs+ P value 
  
 (n = 133) (n = 41)   
Duration of the disease           
(years) 2 (0.5, 5) 5 (3, 10) < 0.001 
Nasal obstruction VAS 
scores 
6 (4, 8) 8 (6, 9) < 0.001 
Rhinorrhea VAS scores 6 (3, 8) 5 (3, 5.5) 0.690 
Headache VAS scores 2 (0, 4.75) 2 (0, 4) 0.466 
Facial pain VAS scores 0 (0, 2) 0 (0, 2) 0.681 
Loss of smell VAS 
scores 
3 (0, 8) 5 (1.75, 8) 0.411 
Total VAS scores 17 (12, 26.5) 19 (15, 24.25) 0.434 
Overall burden VAS 
scores 
6 (5, 8) 7 (5, 8) 0.069 
Total endoscopic scores 8 (6, 10) 8 (6, 9) 0.833 
Total CT scores  14 (8.5, 20) 13 (8, 22) 0.845 
Patients with AR 25 (19%) 7 (17%) 0.803 
Patients with asthma 14 (11%) 3 (7%) 0.765 
Prior surgery 38 (29%) 20 (49%) 0.023 
For continuous variables, results are expressed as medians and interquartile ranges. 565 
Categorical variables are summarized using percentage.  566 
NP, nasal polyp; eLTs, ectopic lymphoid tissues; eLTs-, without eLTs; eLTs+, with 567 
eLTs; VAS, visual analogue scale; CT, computed tomography; AR, allergic rhinitis. 568 
Given to the limited amount of tissue samples, in this study, eLTs were defined as 569 
grade 2 and grade 3 lymphoid aggregates evaluated by hematoxylin and eosin staining. 570 
The rationality is based on our finding that the majority (over 78%) of grade 2 and 571 
grade 3 lymphoid aggregates could be defined as eLTs by immunohistochemistry (see 572 
table 1). 573 
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Figure Legends 574 
Figure E1. Increased formation of lymphoid aggregates in various grades in nasal 575 
polyps (NPs). A, A schematic figure showing the radial cell counting. B, 576 
Representative photomicrographs showing lymphoid aggregates in different grades in 577 
NPs (original magnification × 200) and lymphoid follicle in tonsils (original 578 
magnification × 100) detected by hematoxylin-eosin staining. C, The percentages of 579 
subjects having lymphoid aggregates in different grades. Grade corresponds to the 580 
highest grade of lymphoid aggregations present in a sinonasal mucosal sample. *P < 581 
0.05, compared with controls with aggregate in the same grade. D, The total numbers 582 
of lymphoid aggregates and the number of lymphoid aggregates in different grades 583 
per low power field (LPF) in different study groups. E, Representative 584 
photomicrograph showing lymphoid aggregates in different grades in one polyp 585 
sample (original magnification × 100). ENP, eosinophilic NPs; NENP, 586 
non-eosinophilic NPs. 587 
 588 
Figure E2. Photomicrographs showing tonsil tissue sections stained for CD3, CD20, 589 
CD21, Ki-67, CCL21, CD138, IgE, IgM, IgG, IgA, Ki-67 and CD20, CD4 and 590 
CXCR5, CD20 and CD23, and CD21 and CD23 by immunohistochemistry or 591 
immunofluorescence. Tonsil tissue was employed as positive control for 592 
immunohistochemical and immunofluorescence staining. Original magnification × 593 
200. 594 
 595 
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Figure E3. The protein levels of CXCL13, CCL21, and LTα in tissue homogenates 596 
detected by using ELISA. eLTs-, without ectopic lymphoid tissues; eLTs+, with 597 
ectopic lymphoid tissues; ENP, eosinophilic nasal polyps; NENP, non-eosinophilic 598 
nasal polyps. *P < 0.05; **P < 0.01; ***P < 0.001. 599 
 600 
Figure E4. Representative photomicrographs showing scattered CXCL13+ 601 
mononuclear cells and CCL21+ stromal cells (original magnification × 400), and 602 
CXCR5+ cells, CCR7+ cells, and LTβR+ cells (original magnification × 200) in other 603 
areas in addition to ectopic lymphoid tissues in nasal polyps detected by 604 
immunohistochemistry or immunofluorescence. Insets show a higher magnification of 605 
the outlined area. Arrows denote positive cells. 606 
 607 
Figure E5. A, Increased number of IL-17A+ cells in nasal polyps (NPs). B, 608 
Infiltration of IL-17A+ cells in sinonasal mucosa. Representative photomicrographs 609 
are shown. Original magnification × 400. eLTs-, without ectopic lymphoid tissues; 610 
eLTs+, with ectopic lymphoid tissues; ENP, eosinophilic NPs; NENP, 611 
non-eosinophilic NPs. **P < 0.01; ***P < 0.001. 612 
 613 
Figure E6. Immunofluorescence demonstrated IL-7+ cells in other locations besides 614 
ectopic lymphoid tissues in polyps. Representative photomicrograph is shown. 615 
Original magnification × 200. Inset shows a higher magnification of the outlined area. 616 
Arrow denotes positive cells. 617 
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 618 
Figure E7. Distribution of ICAM1 and VCAM1 positive vessels in other areas in 619 
addition to ectopic lymphoid tissues in nasal polyps. Representative 620 
photomicrographs are shown. Original magnification × 400. 621 
 622 
Figure E8. The frequencies of ICOS+, PD1+, ICOS+PD1+, and IL-21+ T follicular 623 
helper (TFH) cells in total TFH cells in control tissues, and nasal polyps (NPs) with 624 
and without ectopic lymphoid tissues (eLTs) analyzed by flow cytometry. ENP, 625 
eosinophilic NPs; NENP, non-eosinophilic NPs; eLTs-, without eLTs; eLTs+, with 626 
eLTs . *P < 0.05; **P < 0.01; ***P < 0.001. 627 
 628 
Figure E9. Significant positive correlations between the mRNA expression of CD21L 629 
and AID, BAFF and AID, and BAFF and CD21L in polyps with ectopic lymphoid 630 
tissues.  631 
 632 
Figure E10. The levels of immunoglobulins (Igs) in control tissues, eosinophilic 633 
nasal polyps (ENP), and non-eosinophilic nasal polyps (NENP). *P < 0.05; **P < 634 
0.01. 635 
 636 
Figure E11. The fold changes of protein levels of IL-4, IL-5, IL-7, IL-13, IL-17A, 637 
IL-21, and LTα in supernatants of control tissue and eosinophilic polyp tissue explants 638 
stimulated with Der p 1 over those in supernatants of tissue explants from the same 639 
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patient without stimulation. ENP, eosinophilic nasal polyps; eLTs, ectopic lymphoid 640 
tissues; eLTs-, without eLTs; eLTs+, with eLTs. 641 
 642 
Figure E12. The fold changes of protein levels of IL-4, IL-5, IL-7, IL-13, IL-17A, 643 
IL-21, and LTα in supernatants of control tissue and non-eosinophilic polyp tissue 644 
explants stimulated with Der p 1 over those in supernatants of tissue explants from the 645 
same patient without stimulation. NENP, non-eosinophilic nasal polyps; eLTs, ectopic 646 
lymphoid tissues; eLTs-, without eLTs; eLTs+, with eLTs. 647 
 648 
Figure E13. No difference in the frequency of ectopic lymphoid tissue formation in 649 
normal inferior turbinate tissues and normal ethmoid tissues. Normal ethmoid tissues 650 
were collected from 23 patients (age, years, 29 (18, 47); 15 (65%) male) suffering 651 
from nasal trauma, mucocele of frontal or sphenoid sinus, or nasal tumors, and 652 
without ethmoid sinus inflammation on coronal computed tomography scanning and 653 
endoscopy. eLTs, ectopic lymphoid tissues.  654 
 655 
 656 
 657 
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